Glow · 70mg
Research blendGHK-Cu + BPC-157 + TB-500 (50+10+10 mg) · tissue repair + skin and collagen in one vial
Overview
What has it been researched for?
- Repairs tendon, ligament and muscle Main focusEarly evidence
- Closes wounds and ulcersEarly evidence
- Firmer, denser skin: more collagenEarly evidence
- Lowers inflammationEarly evidence
- Protects and repairs the gut liningEarly evidence
- Denser hair, less sheddingEarly evidence
Research protocols
The SBL research protocol and what the literature reports. Not medical advice.
SBL research protocol · no established clinical regimen in people
- Dose
- 1.4 → 2.8 mg
- Frequency
- diario · noche
- Duration
- 12 weeks
- Route
- Subcutaneous
- Evidence level
- Preclinical
Tools
Evidence and studies
See studies →Protocols
Research protocols
SBL research protocol · no established clinical regimen in people
Research use, with no established clinical regimen in people.
- Dose
- 1.4 → 2.8 mg
- Frequency
- diario · noche
- Timing
- noche
- Duration
- 12 weeks
- Break
- 3 weeks
- Route
- Subcutaneous
- Evidence level
- Preclinical
Example dose
30-unit U-100 insulin syringe · Starting dose of its protocol, with 3 ml of water in the 70 mg vial.
What it pairs with
Preparation and dosing
Quick reference
Preparation
- Diluent
- Bacteriostatic water
Evidence
Each effect with its evidence level and, where available, its source.
- Repairs tendon, ligament and musclePreclinicalSee study · 2026
- Closes wounds and ulcersExtrapolatedSee study · 1994
- Firmer, denser skin: more collagenExtrapolatedSee study · 2015
- Lowers inflammationPreclinicalSee study · 1997
- Protects and repairs the gut liningPreclinicalSee study · 2020
- Denser hair, less sheddingExtrapolatedSee study · 2016
The science
Mechanisms, studies and references
GHK + BPC + TB
Safety
It makes sense if you want
- Skin healing & regeneration
- General body recovery
- Recover from an injury (tendon, joint)
It does not make sense if
- Active cancer or oncology treatment in the last 5 years
- Pregnancy or breastfeeding
- Wilson disease or copper allergy
- Severe liver impairment
Talk to your doctor first if this applies (3)
- Anticoagulants (warfarin, rivaroxaban, etc.)
- Cardiovascular disease
- Immunosuppressants
The certificate of analysis (CoA) certifies the identity and purity of the batch. It does not certify safety of use.
Verify your batch →For research use only (RUO). This consult is educational and does not replace your doctor.
Questions
Frequently asked questions
What is it reconstituted with, and how much?
With bacteriostatic water: 3 ml into the 70 mg vial, giving 23.33 mg/ml.
What is the starting dose of the research protocol?
1.4 → 2.8 mg, diario · noche. This is the SBL research protocol, with no established clinical regimen in people.
How long is the cycle, and how long does a vial last?
12 weeks ON / 3 weeks OFF. At the starting dose, the 70 mg vial lasts ~4 sem.
Which route is used in research?
Subcutaneous.
When does it make no sense?
It makes no sense with: Active cancer or oncology treatment in the last 5 years, Pregnancy or breastfeeding, Wilson disease or copper allergy, Severe liver impairment. Details in the Safety tab.
How do I check my batch?
With the code on the vial, in the verifier. The CoA certifies the identity and purity of the batch, not safety of use.
For research use only (RUO). This consult is educational and does not replace your doctor.